WHO to send 70,000 vaccine doses to Congo to curb Ebola
Congo will receive 70,000 doses of the Ervebo vaccine, which has been effective in past Ebola outbreaks, the World Health Organisation and partners said on Thursday, announcing a step seen as a major boost to efforts to contain what officials have described as the fastest Ebola outbreak in history.
The Ervebo vaccine is licensed for use against Ebola virus, one of the viruses that cause Ebola disease, but not for Bundibugyo virus, which is responsible for the current outbreak.
WHO said in a statement that while it’s not known whether Ervebo may protect against the Bundibugyo virus, “early laboratory and animal data suggest it may provide some protection.”
The allocation includes 20,000 doses for a Phase 3 clinical trial to understand the impact of the vaccine on the Bundibugyo virus, the agency said. The remaining 50,000 doses will be used for front-line and health workers as recommended by WHO experts.
